Trial Profile
Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of the Response to Therapy With the Combination of Sunitinib and AMG386 in Metastatic Renal Cell Carcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Jul 2020
Price :
$35
*
At a glance
- Drugs Trebananib (Primary) ; Sunitinib
- Indications Renal cancer
- Focus Therapeutic Use
- 26 Jun 2020 Status changed from suspended to discontinued.
- 18 Nov 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 12 Sep 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.